# Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition

> **NCT04941196** · PHASE1 · COMPLETED · sponsor: **University of Karachi** · enrollment: 30 (actual)

## Conditions studied

- Healthy Individuals

## Interventions

- **DRUG:** Anplag (Ticagrelor 90 mg)
- **DRUG:** Brilinta (Ticagrelor 90 mg)

## Key facts

- **NCT ID:** NCT04941196
- **Lead sponsor:** University of Karachi
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-16
- **Primary completion:** 2020-10-26
- **Final completion:** 2020-11-25
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-09-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04941196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04941196, "Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04941196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*